1. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study.
Lancet Glob Health 2021;9:e130-43.
2. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes.
Diabetes Care 2004;27:Suppl 1. S84-7.
3. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss.
Eye Vis (Lond) 2015;2:17.
4. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy.
Diabetes Care 2012;35:556-64.
5. Thomas RL, Halim S, Gurudas S, et al. IDF Diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015-2018.
Diabetes Res Clin Pract 2019;157:107840.
6. International Diabetes Federation. IDF DM Atlas 2019 [Internet] Brussels: International Diabetes Federation; 2019 [cited 2021 Jan 17]. Available from:
https://diabetesatlas.org/resources/
.
7. Da PT, Nyunt K. Study of diabetic management, control and complications among the patients attending diabetic clinic at PMMPMHAMB Hospital, Tutong district, Brunei Darussalam. Brunei Int Med J 2003;3:33-8.
8. Joshi N, Mathew R, Abdul Momin N. Incidence of diabetic retinopathy in Brunei Darussalam. Brunei Int Med J 2003;3:39-41.
9. Ali NA, George J, Joshi N, Lim MS, Siraj AA. Findings of diabetes eye screening in Brunei Darussalam: REPAS diabetic retinopathy grading scale. Brunei Int Med J 2015;11:182-90.
10. Department of Economic Planning and Statistics. Brunei population snapshot mid-year population estimates 2019 [Internet] Bandar Seri Begawan: Department of Economic Planning and Statistics, Ministry of Finance and Economy; 2019 [cited 2021 Jan 17]. Available from:
http://www.deps.gov.bn/
.
11. Naik S, Wykoff CC, Ou WC, et al. Identification of factors to increase efficacy of telemedicine screening for diabetic retinopathy in endocrinology practices using the Intelligent Retinal Imaging System (IRIS) platform.
Diabetes Res Clin Pract 2018;140:265-70.
12. Kanjee R, Dookeran RI, Mathen MK, et al. Six-year prevalence and incidence of diabetic retinopathy and cost-effectiveness of tele-ophthalmology in Manitoba.
Can J Ophthalmol 2016;51:467-70.
13. Vujosevic S, Pucci P, Casciano M, et al. A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy.
J Diabetes Complications 2017;31:1348-53.
14. Thomas RL, Dunstan FD, Luzio SD, et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service.
Br J Ophthalmol 2015;99:64-8.
15. Rodriguez-Poncelas A, Miravet-Jimenez S, Casellas A, et al. Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain).
Br J Ophthalmol 2015;99:1628-33.
16. Dehghan MH, Katibeh M, Ahmadieh H, et al. Prevalence and risk factors for diabetic retinopathy in the 40 to 80 year-old population in Yazd, Iran: the Yazd Eye Study.
J Diabetes 2015;7:139-41.
17. Ahmed RA, Khalil SN, Al-Qahtani MA. Diabetic retinopathy and the associated risk factors in diabetes type 2 patients in Abha, Saudi Arabia.
J Family Community Med 2016;23:18-24.
18. Sunita M, Singh AK, Rogye A, et al. Prevalence of diabetic retinopathy in urban slums: the Aditya Jyot diabetic retinopathy in urban Mumbai slums study-report 2.
Ophthalmic Epidemiol 2017;24:303-10.
19. Liu Y, Song Y, Tao L, et al. Prevalence of diabetic retinopathy among 13473 patients with diabetes mellitus in China: a cross-sectional epidemiological survey in six provinces.
BMJ Open 2017;7:e013199.
20. Abougalambou SS, Abougalambou AS. Risk factors associated with diabetic retinopathy among type 2 diabetes patients at teaching hospital in Malaysia.
Diabetes Metab Syndr 2015;9:98-103.
21. Tan GS, Gan A, Sabanayagam C, et al. Ethnic differences in the prevalence and risk factors of diabetic retinopathy: the Singapore Epidemiology of Eye Diseases Study.
Ophthalmology 2018;125:529-36.
22. Jongsareejit A, Potisat S, Krairittichai U, et al. The Thai DMS Diabetes Complications (DD.Comp.) project: prevalence and risk factors of diabetic retinopathy in Thai patients with type 2 diabetes mellitus.
J Med Assoc Thai 2013;96:1476-82.
23. Sasongko MB, Widyaputri F, Agni AN, et al. Prevalence of diabetic retinopathy and blindness in Indonesian adults with type 2 diabetes.
Am J Ophthalmol 2017;181:79-87.
24. Jee D, Lee WK, Kang S. Prevalence and risk factors for diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008-2011.
Invest Ophthalmol Vis Sci 2013;54:6827-33.
25. Huang OS, Tay WT, Ong PG, et al. Prevalence and determinants of undiagnosed diabetic retinopathy and vision-threatening retinopathy in a multiethnic Asian cohort: the Singapore Epidemiology of Eye Diseases (SEED) study.
Br J Ophthalmol 2015;99:1614-21.
26. American Diabetes Association. Standards of medical care in diabetes: 2013.
Diabetes Care 2013;36:Suppl 1. (Suppl 1):S11-66.
27. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group.
Ophthalmology 1995;102:647-61.
28. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
BMJ 2000;321:405-12.
29. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study.
Diabetes Care 2010;33:1090-6.
30. Kirkman MS, McCarren M, Shah J, et al. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes.
J Diabetes Complications 2006;20:75-80.
31. ADVANCE Collaborative Group. Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
N Engl J Med 2008;358:2560-72.
32. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med 2008;358:2545-59.
33. Terry T, Raravikar K, Chokrungvaranon N, Reaven PD. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes?: insights from ACCORD, ADVANCE, and VADT.
Curr Cardiol Rep 2012;14:79-88.
34. Chang CH, Chuang LM. Microalbuminuria and diabetic retinopathy in type 2 diabetic patients: from risk association to risk prediction.
J Diabetes Investig 2013;4:42-4.
35. Rajalakshmi R, Shanthi Rani CS, Venkatesan U, et al. Correlation between markers of renal function and sight-threatening diabetic retinopathy in type 2 diabetes: a longitudinal study in an Indian clinic population.
BMJ Open Diabetes Res Care 2020;8:e001325.
36. Do DV, Wang X, Vedula SS, et al. Blood pressure control for diabetic retinopathy.
Cochrane Database Syst Rev 2015;1:CD006127.
37. Frank RN. Systemic therapies for diabetic retinopathy: the accord eye study.
Ophthalmology 2014;121:2295-6.